Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy

Nabil F. Saba, Mayur D. Mody, Elaine S. Tan, Harpaul S. Gill, Alessandra Rinaldo, Robert P. Takes, Primož Strojan, Dana M. Hartl, Jan B. Vermorken, Missak Haigentz, Alfio Ferlito

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) is a difficult to treat malignancy and represents the seventh most common cancer worldwide. Systemic therapy has a critical role in the treatment of locally advanced and recurrent/metastatic disease. Cytotoxic chemotherapy has been primarily used along with radiation and surgery, with cisplatin being the standard of care choice of therapy. When contraindications to cisplatin exist, other agents such as carboplatin, taxanes, 5-fluorouracil, and cetuximab are used. Similarly, in the advanced or metastatic setting, platinum agents, taxanes and cetuximab have been predominantly utilized. With the recent approval of novel agents such as pembrolizumab and nivolumab, and their distinct toxicity profiles, an understanding of the potential sequelae of the different systemic agents is essential to the careful selection of agents in the advanced disease setting. Going forward, choosing novel agents will be weighed against traditional chemotherapy, and understanding the toxicities at stake is critical in this process. In addition to providing an overview of the toxicity profile of the different systemic agents, we also provide a perspective into the future of SCCHN treatment.

Original languageEnglish (US)
Pages (from-to)50-58
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume115
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Immunotherapy
Taxoids
Cisplatin
Drug Therapy
Carboplatin
Therapeutics
Standard of Care
Platinum
Fluorouracil
Neoplasms
Radiation
Carcinoma, squamous cell of head and neck
Cetuximab

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Saba, Nabil F. ; Mody, Mayur D. ; Tan, Elaine S. ; Gill, Harpaul S. ; Rinaldo, Alessandra ; Takes, Robert P. ; Strojan, Primož ; Hartl, Dana M. ; Vermorken, Jan B. ; Haigentz, Missak ; Ferlito, Alfio. / Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 115. pp. 50-58.
@article{e4e8dfbdd0294728b3b7432bf0d96499,
title = "Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy",
abstract = "Squamous cell carcinoma of the head and neck (SCCHN) is a difficult to treat malignancy and represents the seventh most common cancer worldwide. Systemic therapy has a critical role in the treatment of locally advanced and recurrent/metastatic disease. Cytotoxic chemotherapy has been primarily used along with radiation and surgery, with cisplatin being the standard of care choice of therapy. When contraindications to cisplatin exist, other agents such as carboplatin, taxanes, 5-fluorouracil, and cetuximab are used. Similarly, in the advanced or metastatic setting, platinum agents, taxanes and cetuximab have been predominantly utilized. With the recent approval of novel agents such as pembrolizumab and nivolumab, and their distinct toxicity profiles, an understanding of the potential sequelae of the different systemic agents is essential to the careful selection of agents in the advanced disease setting. Going forward, choosing novel agents will be weighed against traditional chemotherapy, and understanding the toxicities at stake is critical in this process. In addition to providing an overview of the toxicity profile of the different systemic agents, we also provide a perspective into the future of SCCHN treatment.",
author = "Saba, {Nabil F.} and Mody, {Mayur D.} and Tan, {Elaine S.} and Gill, {Harpaul S.} and Alessandra Rinaldo and Takes, {Robert P.} and Primož Strojan and Hartl, {Dana M.} and Vermorken, {Jan B.} and Missak Haigentz and Alfio Ferlito",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.critrevonc.2017.04.011",
language = "English (US)",
volume = "115",
pages = "50--58",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. / Saba, Nabil F.; Mody, Mayur D.; Tan, Elaine S.; Gill, Harpaul S.; Rinaldo, Alessandra; Takes, Robert P.; Strojan, Primož; Hartl, Dana M.; Vermorken, Jan B.; Haigentz, Missak; Ferlito, Alfio.

In: Critical Reviews in Oncology/Hematology, Vol. 115, 01.07.2017, p. 50-58.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy

AU - Saba, Nabil F.

AU - Mody, Mayur D.

AU - Tan, Elaine S.

AU - Gill, Harpaul S.

AU - Rinaldo, Alessandra

AU - Takes, Robert P.

AU - Strojan, Primož

AU - Hartl, Dana M.

AU - Vermorken, Jan B.

AU - Haigentz, Missak

AU - Ferlito, Alfio

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Squamous cell carcinoma of the head and neck (SCCHN) is a difficult to treat malignancy and represents the seventh most common cancer worldwide. Systemic therapy has a critical role in the treatment of locally advanced and recurrent/metastatic disease. Cytotoxic chemotherapy has been primarily used along with radiation and surgery, with cisplatin being the standard of care choice of therapy. When contraindications to cisplatin exist, other agents such as carboplatin, taxanes, 5-fluorouracil, and cetuximab are used. Similarly, in the advanced or metastatic setting, platinum agents, taxanes and cetuximab have been predominantly utilized. With the recent approval of novel agents such as pembrolizumab and nivolumab, and their distinct toxicity profiles, an understanding of the potential sequelae of the different systemic agents is essential to the careful selection of agents in the advanced disease setting. Going forward, choosing novel agents will be weighed against traditional chemotherapy, and understanding the toxicities at stake is critical in this process. In addition to providing an overview of the toxicity profile of the different systemic agents, we also provide a perspective into the future of SCCHN treatment.

AB - Squamous cell carcinoma of the head and neck (SCCHN) is a difficult to treat malignancy and represents the seventh most common cancer worldwide. Systemic therapy has a critical role in the treatment of locally advanced and recurrent/metastatic disease. Cytotoxic chemotherapy has been primarily used along with radiation and surgery, with cisplatin being the standard of care choice of therapy. When contraindications to cisplatin exist, other agents such as carboplatin, taxanes, 5-fluorouracil, and cetuximab are used. Similarly, in the advanced or metastatic setting, platinum agents, taxanes and cetuximab have been predominantly utilized. With the recent approval of novel agents such as pembrolizumab and nivolumab, and their distinct toxicity profiles, an understanding of the potential sequelae of the different systemic agents is essential to the careful selection of agents in the advanced disease setting. Going forward, choosing novel agents will be weighed against traditional chemotherapy, and understanding the toxicities at stake is critical in this process. In addition to providing an overview of the toxicity profile of the different systemic agents, we also provide a perspective into the future of SCCHN treatment.

UR - http://www.scopus.com/inward/record.url?scp=85024844908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024844908&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.04.011

DO - 10.1016/j.critrevonc.2017.04.011

M3 - Review article

C2 - 28602169

AN - SCOPUS:85024844908

VL - 115

SP - 50

EP - 58

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -